News New Anti-VEGF Agent Brolucizumab Shows Promise for AMD by Medscape • 2017/10/12 • 0 Comments According to new research, brolucizumab, a new anti-VEGF for neovascular AMD, is noninferior to aflibercept and may offer longer dosing intervals. Medscape Ophthalmology Full Story →